Skylark Bio Receives Green Light to Expand Pediatric Hearing Loss Gene Therapy Trial

skylark bio gene therapy hearing loss
HHTM
November 18, 2026

CAMBRIDGE, MASSACHUSETTS — Skylark Bio announced that an independent Data Safety Monitoring Board (DSMB) has unanimously recommended advancing its investigational gene therapy, SKY-GJB2, into the next stage of the SONIX Phase 1/2 clinical trial. The decision follows a review of safety data from the first four children treated in the study, allowing researchers to begin enrolling younger participants.

The next cohort will include children aged 9 months to under 2 years, expanding the study beyond its initial group of participants aged 2 to 7 years.

The development represents an important step for the first clinical trial evaluating gene therapy specifically for hearing loss caused by mutations in the GJB2 gene, one of the most common genetic causes of childhood deafness. The study began treating participants earlier this year, with Skylark Bio announcing the first patient dosing in August.

Safety Review Supports Expansion to Younger Children

The SONIX trial is a first-in-human, multicenter Phase 1/2 study evaluating the safety, tolerability, and preliminary effectiveness of SKY-GJB2 in children with GJB2-related hearing loss.

The independent DSMB reviewed available safety information from four children who received treatment in the trial’s initial dose cohort. Following that review, the board unanimously recommended that the study proceed to its second cohort.

Although the recommendation supports continued enrollment, it does not establish whether the investigational treatment improves hearing. The trial is still in its early stages, and clinical effectiveness data have not yet been publicly presented.

“The DSMB’s recommendation marks an important milestone for the SKY-GJB2 program and supports continued advancement of SONIX into younger children during a critical period of auditory and language development. We are encouraged by the safety profile observed to date and remain enthusiastic about the potential of SKY-GJB2 to address the underlying cause of GJB2-mediated hearing loss and transform outcomes for affected children and their families. We are grateful to the participating families, investigators, and site personnel whose partnership has made this progress possible.”

–Jodi Cook, Ph.D., Chief Executive Officer of Skylark Bio

Targeting the Genetic Cause of Hearing Loss

Mutations in the GJB2 gene are among the leading causes of inherited nonsyndromic hearing loss worldwide. The gene provides instructions for producing connexin 26, a protein that plays an essential role in communication between cells within the inner ear.

Connexin 26 is particularly important for maintaining the cellular environment necessary for normal cochlear function. When mutations disrupt this protein, the resulting changes can interfere with hearing.

Unlike hearing aids and cochlear implants, which provide access to sound without correcting the underlying genetic cause, SKY-GJB2 is being developed to address the biological mechanism responsible for the hearing loss.

The investigational therapy is designed to deliver a functional copy of the GJB2 gene to supporting cells within the cochlea. The goal is to restore the gap-junction network that depends on connexin 26 and potentially improve hearing function.

Treatment involves a single injection into one cochlea, allowing researchers to evaluate the therapy’s safety and potential effects on hearing.

In a recent This Week in Hearing discussion with Brian Taylor, AuD, Skylark Bio CEO Jodi Cook, PhD, and Clinical Development Scientist Alexa Kozak, AuD, MBA, explained the science behind SKY-GJB2, the design of the SONIX trial, and the growing importance of genetic testing in pediatric audiology. They also discussed how emerging genetic therapies could eventually complement established interventions such as hearing aids and cochlear implants.

Why Earlier Treatment May Matter

The decision to enroll children younger than 2 years is particularly relevant because early childhood represents an important period for auditory and spoken-language development.

For children born with significant hearing loss, early access to auditory information can influence the development of speech perception and communication skills.

Researchers are investigating whether addressing the underlying genetic cause during this developmental period could provide meaningful hearing improvements. However, the extent to which gene therapy might restore auditory function, and how those changes could affect language development, remains to be determined.

The SONIX study is designed to evaluate these questions while continuing to monitor treatment safety.

Initial Clinical Results Expected in 2027

Skylark Bio reports that the SONIX trial remains on track to generate preliminary clinical data by the end of 2026, with initial results expected to be presented in 2027.

The trial’s primary objectives include evaluating safety and tolerability, along with preliminary evidence of improved hearing following treatment.

The company’s announcement did not provide specific audiometric outcomes from the four children treated in the initial cohort.

For hearing care professionals and researchers following developments in genetic hearing loss, the advancement of SONIX represents another step toward evaluating treatments that target the underlying causes of inherited deafness rather than relying exclusively on amplification or electrical stimulation.

While substantial questions remain about long-term safety, treatment effectiveness, and which patients may benefit, the expansion into younger children will provide additional information about the potential clinical application of SKY-GJB2.

Additional information about the trial is available through the SONIX study website.

About Skylark Bio

Skylark Bio is a clinical-stage genetic medicine company developing precision, locally delivered gene therapies for monogenic diseases, with the potential to meaningfully improve patient outcomes and quality of life. The company’s lead program, SKY-GJB2, is being evaluated in SONIX, a Phase 1/2 clinical trial for GJB2-related hearing loss, the leading cause of inherited hearing loss worldwide. Additional programs include SKY-PEN for SLC26A4-related hearing loss and an undisclosed program in CNS.

Skylark’s proprietary gene therapy platform is built on an engineered capsid designed for broad transduction, with targeted microdose delivery, cell-specific expression control, and durable benefit. Led by a team with deep expertise in gene therapy and supported by world-class advisors, Skylark is advancing a pipeline of innovative therapies for hearing loss and other genetic disorders that profoundly impact patients and families.

 

Source: Skylark Bio

Email Marketing by Benchmark